<DOC>
	<DOCNO>NCT02459886</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability range single BIIB054 dos , administer single intravenous ( IV ) infusion , healthy participant participant early Parkinson 's disease ( PD ) . Secondary objective study assess serum pharmacokinetics ( PK ) profile BIIB054 single-dose administration evaluate immunogenicity BIIB054 single-dose administration .</brief_summary>
	<brief_title>Single-Ascending Dose Study BIIB054 Healthy Participants Early Parkinson 's Disease</brief_title>
	<detailed_description>Only healthy participant enrol Cohorts 1 6 . Only participants early PD enrol Cohort 7</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Key 1 . All woman childbearing potential men must practice effective contraception study 6 month last dose study treatment . 2 . Must body mass index 19 32 kg/m2 , inclusive . 3 . Must good health determine Investigator , base medical history , physical examination , 12lead ECG . For cohort 7 : 4 . Diagnosis idiopathic PD 5 . Not receive symptomatic PD treatment . Key 1 . History cardiovascular disease . 2 . Subject smoke 5 cigarette equivalent tobacco daily . 3 . Surgery within 3 month prior Day 1 ( minor cosmetic surgery minor dental surgery , determine Investigator ) . 4 . History positive test result hepatitis C , hepatitis B , human immunodeficiency virus ( HIV ) . 5 . Female subject pregnant , currently breastfeed , attempt conceive study . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>alpha synuclein</keyword>
	<keyword>PD</keyword>
</DOC>